TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16487912

Group type: EXPERIMENTAL
Intervention: PUFA n‐3 and vitamin E (group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined PUFA n‐3, vitamin E, gamma‐oryzanol, and niacin (group C)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 57
Study: 16117967

Group type: EXPERIMENTAL
Intervention: CQ + AS (4 mg/kg bodyweight daily for 3 days)
Number of subjects: 400

Group type: COMPARATOR
Intervention: CQ (25 mg/kg bodyweight over 3 days)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: CQ + AS
Number of subjects: 400

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 400
Study: 10836728

Group type: EXPERIMENTAL
Intervention: Manidipine (M) 10-20 mg, od, for 24 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Enalapril (E) 10-20 mg, od, for 24 weeks
Number of subjects: 101
Study: 9376779

Group type: EXPERIMENTAL
Intervention: bromocriptine 25 mg
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: bromocriptine 50 mg
Number of subjects: 366

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 366
Study: 1317178

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.002, 0.004, and 0.007 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular glycopyrrolate (0.0044 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (young subjects)
Number of subjects: 0
Study: 3910428

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg i.m. before anaesthesia
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg i.v. at the end of anaesthesia
Number of subjects: 112

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Droperidol (i.m. or i.v.)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 112
Study: 30201408

Group type: EXPERIMENTAL
Intervention: 600 mg BMS-986020 (bid)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 600 mg BMS-986020 (qd)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 25756560

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2062
Study: 25985851

Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000 IU retinyl palmitate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (one capsule of placebo per day)
Number of subjects: 36
Study: 23768842

Group type: EXPERIMENTAL
Intervention: 8 puffs on arrival and 2 puffs/trial ("8+2")
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2 puffs/trial only ("0+2")
Number of subjects: 23

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 23
Study: 21600390

Group type: EXPERIMENTAL
Intervention: Test drug (generic Mycophenolate mofetil 500 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reference drug (branded Mycophenolate mofetil 500 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both test and reference drugs
Number of subjects: 126
Study: 19713965

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Losartan (50 mg daily)
Number of subjects: 30
Study: 16449345

Group type: EXPERIMENTAL
Intervention: SR 49059 (200 mg once daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15033935

Group type: EXPERIMENTAL
Intervention: Oral tertatolol (nonselective beta-antagonist) treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)
Number of subjects: 0
Study: 11284814

Group type: EXPERIMENTAL
Intervention: Sevoflurane in nitrous oxide-oxygen (2 : 1 l.min‐1)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intravenous fentanyl 1 microg.kg‐1 + propofol 2 mg.kg‐1 followed by nitrous oxide-oxygen (2 : 1 l.min‐1) and sevoflurane
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intravenous fentanyl + propofol
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 9307536

Group type: EXPERIMENTAL
Intervention: Single dose of prostaglandin E2 2 mg vaginal gel
Number of subjects: 995

Group type: COMPARATOR
Intervention: Two doses of prostaglandin E2 (2 mg each, second dose after six hours if needed)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Two doses of prostaglandin E2 (2 mg each)
Number of subjects: 995
Study: 8025745

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 500 micrograms twice per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2917833

Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 60
Study: 1131804

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil plus diethylstilbestrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: diethylstilbestrol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCNU
Number of subjects: 0
Study: 30780190

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study: 28777127

Group type: EXPERIMENTAL
Intervention: Individualized vibrotactile neurofeedback training (IVNT) for ∼10 minutes each day for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized vibrotactile neurofeedback training (IVNT) combined with oral medication (20 mg cinnarizine and 40 mg dimenhydrinate, three tablets per day)
Number of subjects: 0
Study: 26399571

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Weekly check-in control group
Number of subjects: 140
Study: 25044795

Group type: EXPERIMENTAL
Intervention: Food formulations with unsaturated/saturated fat and beetroot extract
Number of subjects: 16
Study: 22840549

Group type: EXPERIMENTAL
Intervention: ARC intervention
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197
Study: 20377532

Group type: EXPERIMENTAL
Intervention: Neopuff (NP) mode with pressure dial visible
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chest wall movement (CWM) mode with pressure dial hidden
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both modes (CWM and NPM)
Number of subjects: 36
Study: 18656756

Group type: EXPERIMENTAL
Intervention: Dynamic protocol using a rubber-band system (DY)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Early active thumb extension with limited flexion (AC)
Number of subjects: 21
Study: 16050405

Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (LLDN)
Number of subjects: 50
Study: 12774158

Group type: EXPERIMENTAL
Intervention: Infant Flow System
Number of subjects: 20

Group type: COMPARATOR
Intervention: Babylog 8000
Number of subjects: 20
Study: 10386681

Group type: EXPERIMENTAL
Intervention: Algorithm I (A-I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Algorithm II (A-II)
Number of subjects: 36
Study: 9058311

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-beta (IFN-beta) 6 million units, three times per week for 6 months
Number of subjects: 15
Study: 8215790

Group type: EXPERIMENTAL
Intervention: Perindopril 1 mg/Kg/day for 5 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 11
Study: 3525237

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 200 mg intramuscularly every 14 days for six injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30184023

Group type: EXPERIMENTAL
Intervention: Functional constipation
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Overactive bladder
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Dry overactive bladder
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Wet overactive bladder
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Functional constipation predicting dry overactive bladder
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Quality of life in constipated women
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Manual maneuvers
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: <3 defecations/week
Number of subjects: 516
Study: 27354125

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intensity Modulated Photon Therapy (IMRT)
Number of subjects: 81
Study: 25547978

Group type: EXPERIMENTAL
Intervention: Training programme for GPs on action planning (1 hour)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Highly specific action plan enactment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Plan specificity and enactment
Number of subjects: 49
Study: 22863640

Group type: COMPARATOR
Intervention: Aged Maggi™ placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fresh Maggi™ placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aged artificial food coloring placebo with licorice flavor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: STW5
Number of subjects: 60
Study: 20427546

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4 x 4.5 g IV/day)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Carbapenem (meropenem 3 x 1 g IV/day or imipenem 4 x 500 mg IV/day) with or without amikacin (1 g IV/day)
Number of subjects: 127
Study: 18985695

Group type: EXPERIMENTAL
Intervention: Birth Defects Cluster Study intervention (case-control study design with standardized methods)
Number of subjects: 0
Study: 19667717

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors (general)
Number of subjects: 0
Study: 12891643

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cholinesterase therapy (control)
Number of subjects: 0
Study: 10579145

Group type: EXPERIMENTAL
Intervention: Citracal (calcium citrate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Os-Cal (calcium carbonate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8768828

Group type: EXPERIMENTAL
Intervention: 5 mg MK-677
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25 mg MK-677
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 9
Study: 8332270

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Propranolol and Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3298404

Group type: EXPERIMENTAL
Intervention: Acyclovir, 45 mg/kg/day by continuous intravenous infusion for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 30
Study: 29663857

Group type: EXPERIMENTAL
Intervention: Brain training program with weekly supervision (600 min playtime)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Passive intervention with supervision twice (offered after trial)
Number of subjects: 105
Study: 27716229

Group type: COMPARATOR
Intervention: Ropivacaine (20 mL of 0.375%)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ropivacaine with betamethasone (19 mL of 0.375% ropivacaine + 4 mg betamethasone)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 44
Study: 24300220

Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 20 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 40 mg
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 22057753

Group type: EXPERIMENTAL
Intervention: Limberg flap (group 1)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Tension-free primary closure (group 2)
Number of subjects: 93
Study: 20195587

Group type: COMPARATOR
Intervention: Non-chiral method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiral method (sum of enantiomers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiral method (S-ibuprofen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chiral method (R-ibuprofen)
Number of subjects: 0
Study: 18054932

Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No cetrorelix (group I)
Number of subjects: 61
Study: 16779569

Group type: EXPERIMENTAL
Intervention: Standard trabeculectomy (Group 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Releasable suture trabeculectomy (Group 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 12824908

Group type: EXPERIMENTAL
Intervention: Vitamin C 50 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg/day
Number of subjects: 244
Study: 10547556

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of doxorubicin or epirubicin after TUR
Number of subjects: 1732

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy
Number of subjects: 1732
Study: 8708495

Group type: EXPERIMENTAL
Intervention: Procaterol delivered by metered-dose inhaler (MDI) with paper spacer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Procaterol delivered by metered-dose inhaler (MDI) without spacer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Procaterol delivered by MDI with paper spacer
Number of subjects: 30
Study: 1928683

Group type: EXPERIMENTAL
Intervention: Propofol anaesthetic using infusion technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol anaesthetic using repeat bolus technique
Number of subjects: 40
Study: 7133972

Group type: EXPERIMENTAL
Intervention: 600 mg of pirprofen
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 1200 mg of pirprofen
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 31912958

Group type: EXPERIMENTAL
Intervention: Low dose carbon monoxide inhalation (1.2 ml/kg for men; 1.0 ml/kg for women)
Number of subjects: 11
Study: 30412235

Group type: EXPERIMENTAL
Intervention: Postrule period (July-December 2017)
Number of subjects: 17937

Group type: COMPARATOR
Intervention: Baseline period (July-December 2016)
Number of subjects: 17937

Group type: EXPERIMENTAL
Intervention: Overall opioid prescribing
Number of subjects: 17937
Study: 28257388

Group type: EXPERIMENTAL
Intervention: Single-shot ultrasound-guided SSNB (10 mL ropivacaine 1%)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Interscalene brachial plexus block (ISB) (20 mL ropivacaine 0.75%)
Number of subjects: 168
Study: 25413170

Group type: EXPERIMENTAL
Intervention: Early Rehabilitation Intervention (ERI)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Brief Education Intervention (BEI)
Number of subjects: 184
Study: 25157767

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m), Carboplatin (AUC 6), Bevacizumab (15 mg/kg) administered on day 1 of each 21-day cycle for up to six cycles, followed by maintenance pemetrexed and bevacizumab.
Number of subjects: 57
Study: 22029398

Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM; supervised methadone with emergency counseling for the first 4 months)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Standard Methadone (SM; with routine counseling)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Restored Methadone (RM; routine counseling with smaller case-loads)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Standard Methadone (SM)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Restored Methadone (RM)
Number of subjects: 230

Group type: COMPARATOR
Intervention: All groups (IM, SM, RM)
Number of subjects: 230
Study: 19240178

Group type: EXPERIMENTAL
Intervention: High expression of MRP8
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRP8-transfected LLC-PK1 cells
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRP8-enriched membrane vesicles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MRP8-transfected cells
Number of subjects: 50
Study: 17326056

Group type: EXPERIMENTAL
Intervention: B-cell subtype NHL
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: T-cell subtype NHL
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: B-cell NHL with HBV infection
Number of subjects: 587

Group type: COMPARATOR
Intervention: B-cell NHL
Number of subjects: 587
Study: 15044641

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg/kg IV every 12 hours for one week, then tapered)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 146
Study: 11370826

Group type: EXPERIMENTAL
Intervention: OND 32 mg for the first 24 hours, followed by 8 mg every 8 hours for the following four days, combined with dexamethasone 8 mg i.v. the first day and 8 mg p.o. for the following three days.
Number of subjects: 110

Group type: COMPARATOR
Intervention: OND 8 mg every day for 4 days, combined with dexamethasone 8 mg i.v. and 8 mg p.o. for the following three days.
Number of subjects: 110
Study: 9426013

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 312
Study: 7798429

Group type: COMPARATOR
Intervention: Tetracycline 500 mg, taken twice daily for 3 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tab. Gugulipid (equivalent to 25 mg guggulsterone), taken twice daily for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gugulipid
Number of subjects: 20
Study: 3201130

Group type: EXPERIMENTAL
Intervention: 10 ml antacid
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 15
Study: 30842037

Group type: EXPERIMENTAL
Intervention: Anodal so-tDCS bifrontaly at a frequency of 0.75 Hz
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 23
Study: 28742529

Group type: EXPERIMENTAL
Intervention: Empiric tuberculosis therapy
Number of subjects: 850

Group type: COMPARATOR
Intervention: Preventive tuberculosis therapy
Number of subjects: 850
Study: 25199496

Group type: EXPERIMENTAL
Intervention: Synthetic mesh repair (Prolift™)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 184
Study: 22941391

Group type: EXPERIMENTAL
Intervention: Provox Vega Indwelling voice prosthesis
Number of subjects: 23
Study: 21249529

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 47

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both toothbrush methods
Number of subjects: 47
Study: 18972914

Group type: EXPERIMENTAL
Intervention: Preoperative kinesic treatment (K)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (NK)
Number of subjects: 38
Study: 16554988

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per hour SiV for 4 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 14
Study: 14712952

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPI)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Continuous midwifery support (CMS)
Number of subjects: 992
Study: 10730796

Group type: EXPERIMENTAL
Intervention: One-hour CBE retraining session
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no CBE retraining)
Number of subjects: 30
Study: 8957211

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IMAL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dextran sulphate adsorption (DSAL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heparin‐induced extracorporeal LDL precipitation (HELP)
Number of subjects: 7
Study: 1555059

Group type: EXPERIMENTAL
Intervention: Calcium (1.5 g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3505731

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5-15.0 mg (mean elimination half-life approximately 2 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.125-0.25 mg (mean elimination half-life approximately 5 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in bed
Number of subjects: 0
Study: 31033786

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus rhamnosus) at a concentration of 5×10^9 CFU per sachet, administered twice daily by mouth.
Number of subjects: 0
Study: 29055531

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with agalsidase alfa
Number of subjects: 0
Study: 27611038

Group type: EXPERIMENTAL
Intervention: Parenteral paracetamol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enteral paracetamol
Number of subjects: 50
Study: 24685020

Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds powder
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22991347

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 2878

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2878
Study: 21242601

Group type: EXPERIMENTAL
Intervention: School-based physical activity program
Number of subjects: 540

Group type: COMPARATOR
Intervention: No-PA control condition
Number of subjects: 540
Study: 17081535

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg from days 5‐9 of the cycle
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and metformin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 154
Study: 15910350

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levobupivacaine 0.2% (group L)
Number of subjects: 60
Study: 12559939

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265